ANAB · AnaptysBio, Inc. · Stock research

Current Thesis

The binary this whole equity was built around has already happened, and it produced nothing to trade. The Delaware Chancery bench trial in the Tesaro/GSK dispute ran July 14–17, 2026 and closed with no verdict and no buyout headline. The crowd that had positioned for a clean win or a quick GSK take-out unwound into the close: ANAB slid roughly 11% into the trial week (to $55.76 around July 14) and dropped a further ~13% on July 20, finishing at $54.15 on July 24 — a full round-trip of the post-spin advance that had carried it to the $73.30 52-week high. What remains is a pure-play royalty stub (Jemperli/GSK, imsidolimab/Vanda) whose fate now sits with a Vice Chancellor's post-trial written opinion deciding whether Jemperli royalty rights revert to Anaptys or Tesaro's royalty-cut path reopens. That opinion has no public date and can land weeks to months after closing arguments. This is a low-beta coin-flip with the timer removed — no accelerating tape, no cluster, nothing a narrative-momentum book is built to catch.

Bullish and bearish views on AnaptysBio, Inc.

The model's bull view on AnaptysBio, Inc. (ANAB), in brief: Royalty annuity on a growing PD-1. Jemperli (dostarlimab) pays a tiered 8–25% royalty, reaching 25% above $2.5B net sales, with peak sales projected north of $2.7B and composition-of-matter coverage into the mid-2030s — a non-dilutive recurring stream on a GSK oncology franchise… The bear view: The catalyst fired and delivered nothing. Both cases follow in full.

Bull Case

• Royalty annuity on a growing PD-1. Jemperli (dostarlimab) pays a tiered 8–25% royalty, reaching 25% above $2.5B net sales, with peak sales projected north of $2.7B and composition-of-matter coverage into the mid-2030s — a non-dilutive recurring stream on a GSK oncology franchise still adding indications. Roughly $390M of annualized royalty value is what the litigation contests.
• Legal momentum from April. The April 24, 2026 pre-trial ruling dismissed Tesaro's anticipatory-breach claim and rejected its royalty-reduction request, popping the stock ~12% on April 27; Anaptys's own reversion claims survived into the July trial. A favorable written opinion could recapture full Jemperli economics, not merely preserve the rate.
• Clean post-spin balance sheet. The First Tracks (Nasdaq: TRAX) spin completed April 20, 2026 offloaded the clinical pipeline and cash burn; ANAB carries ~$140–145M net cash with no R&D drain — a royalty book plus a legal option.
• Sell-side still constructive. Consensus Buy with an average target near $75 versus $54.15 spot (~+39%), a range from UBS $60 (Apr 21) to Piper $93 (May 4) and HC Wainwright $95 (Jun 10), and no published sells.
• Second dated royalty trigger. Imsidolimab (Vanda) carries an FDA action date of December 12, 2026 for generalized pustular psoriasis, with Phase III data in NEJM (~Apr 29, 2026); approval adds a stream at no incremental ANAB cost.

Bear Case

• The catalyst fired and delivered nothing. The July 14–17 trial ended with no ruling and no deal; the two July gap-downs (to $55.76 mid-month, then ~-13% on July 20) are the market unwinding the clean-win-or-buyout bet in real time.
• The timer is gone. A Chancery post-trial opinion routinely arrives weeks to months after closing arguments. The equity can drift with no catalyst and no momentum for an indeterminate stretch — dead money with a binary tail.
• Court outcomes aren't modellable. An adverse opinion vaporizes the reversion option and reopens Tesaro's royalty-cut path; there is no analytical edge in handicapping a bench ruling.
• Single-counterparty dependence. Value rides entirely on GSK's execution of Jemperli — any deprioritization or label setback hits the annuity, and the pipeline that could have offset it left with TRAX on April 20.
• Broken price structure. Down from the $73.30 high to $54, below where it traded pre-trial, with beta ~0.41 — it moves on legal headlines, not the tape, so there is no trend for a momentum vehicle to lean on.

Setup & Price Structure

• Spot $54.15 (Jul 24, 2026); 52-week range $17.11–$73.30. The name has surrendered its entire post-spin advance — the April 27 ruling pop and the run to $73.30 have fully reversed.
• Two distinct July down legs: ~-11% into the trial week (to $55.76 around July 14) and ~-13% on July 20 as quick-resolution longs exited. Price is now consolidating in the low-$50s.
• The post-spin base built since the April 20 completion sits near $50; the April court-ruling gap fills into the mid-$40s beneath it. There is no momentum shelf to buy against.
• For a narrative-velocity entry there is nothing here: no accelerating tape, no peer cluster, a dateless binary. The disciplined read is to stand aside until either the opinion prints or a fresh base plus catalyst forms.

Catalyst Calendar (next 30 days)

• Delaware Chancery post-trial written opinion — no fixed date. Trial closed July 17, 2026; the opinion can arrive weeks to months out. This is the dominant driver — expect a violent ±20–40% gap whenever it lands.
• Q2 2026 results — est. ~early-to-mid August 2026 (10-Q for the quarter ended June 30; exact date unconfirmed). A royalty run-rate and cash update; second-order for a legal-binary name.
• Imsidolimab (Vanda) FDA action date — 2026-12-12 (beyond the 30-day window; flagged as the next dated event after the opinion).

What Would Change Our Mind

A favorable written opinion granting Jemperli reversion re-rates the equity toward the $95–140 upside band and converts the stub into a full-economics royalty book — that is the accelerant that would make this tradeable on strength rather than on hope. On the downside, a weekly close below $48 breaks the post-spin base and signals the market pricing an adverse ruling, with the April gap toward the mid-$40s opening beneath. A GSK settlement or buyout headline collapses the range either way inside 24 hours. Confirmation that the opinion is slipping into Q4 simply extends the dead-money limbo and lowers any reason to carry exposure through it.

Correlation Notes

• Idiosyncratic and low-beta (~0.41): the name drives on legal and royalty headlines, not the broad tape or biotech beta (XBI/IBB). It is a poor hedge and a poor momentum vehicle.
• Loosely linked to GSK as partner/counterparty and to First Tracks (TRAX) as the sibling equity holding the old pipeline, but the two have traded on separate stories since the April 20 spin completed.
• The closer cohort is event-driven royalty and litigation special-situations (e.g. XOMA Royalty), not precision-biotech momentum — the old SGMT/biotech-precision peer framing left with the spin and should not be reintroduced.